Evidence map›Paper›PMID 35239204›Full record

Trial reportEuropean journal of heart failure2022

Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.

Gerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, Dimitrios Farmakis, Luis M Ruilope, Peter Rossing, Johann Bauersachs, Robert J Mentz, Peter Kolkhof, Charlie Scott and 4 more

Open access · hybridAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in European journal of heart failure, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 4 pooled it
10.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 72 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 12 institutions in 7 countries.

Gerasimos FilippatosNational and Kapodistrian University of Athens, School of Medicine, Department of Cardiology, Attikon University Hospital, Athens, Greece.
Bertram PittDepartment of Medicine, University of Michigan School of Medicine, Ann Arbor, MI, USA.
Rajiv AgarwalRichard L. Roudebush VA Medical Center and Indiana University, Indianapolis, IN, USA.
Dimitrios FarmakisUniversity of Cyprus Medical School, Nicosia, Cyprus.
Luis M RuilopeCardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain.
Peter RossingSteno Diabetes Center Copenhagen, Gentofte, Denmark.
Johann BauersachsDepartment of Cardiology and Angiology, Hannover Medical School, Hannover, Germany.
Robert J MentzDepartment of Medicine, Duke University School of Medicine, Durham, NC, USA.
Peter KolkhofResearch and Development, Preclinical Research Cardiovascular, Bayer AG, Wuppertal, Germany.
Charlie ScottData Science and Analytics, Bayer PLC, Reading, UK.
Amer JosephCardiology and Nephrology Clinical Development, Bayer AG, Berlin, Germany.
George L BakrisDepartment of Medicine, University of Chicago Medicine, Chicago, IL, USA.
Stefan D AnkerDepartment of Cardiology (CVK) and Berlin Institute of Health Center for Regenerative Therapies, German Center for Cardiovascular Research Partner Site Berlin, Charité - Universitätsmedizin, Berlin, Germany.
FIDELIO-DKD Investigators
Bayer (Germany) · DEBayer (United Kingdom) · GBBerlin Institute of Health at Charité - Universitätsmedizin Berlin · DEDuke University · USMedizinische Hochschule Hannover · DENational and Kapodistrian University of Athens · GRRichard L. Roudebush VA Medical Center · USUniversidad Europea de Madrid · ESUniversity of Chicago · USUniversity of Copenhagen · DKUniversity of Cyprus · CYUniversity of Michigan–Ann Arbor · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis prespecified analysis of the FIDELIO-DKD trial compared the effects of finerenone, a selective non-steroidal mineralocorticoid receptor antagonist, on cardiorenal outcomes in patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) by history of heart failure (HF). METHODS AND

resultsPatients with T2D and CKD (urine albumin-to-creatinine ratio ≥30-5000 mg/g and estimated glomerular filtration rate [eGFR] ≥25-<75 ml/min/1.73 m

conclusionIn FIDELIO-DKD, finerenone improved cardiorenal outcome in patients with CKD and T2D irrespective of baseline HF history.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesHeart FailureRenal Insufficiency, ChronicDouble-Blind MethodHumansMineralocorticoid Receptor AntagonistsNaphthyridinesfinerenoneMineralocorticoid Receptor AntagonistsNaphthyridinesAldosteroneChronic kidney diseaseDiabetesFinerenoneHeart failureMineralocorticoid receptor antagonists

Identifiers

PMID35239204
PMCPMC9541504
OpenAlexW4214897998

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.